15 Jun 2012, BioSpectrum Bureau , BioSpectrum
Singapore: ProBioGen, a German contract development and manufacturing organization, has developed and implemented the Pathway Modulator Technology, a permanent modification of animal cell lines for substantially improved protein yields. The Pathway Modulator Technology is royalty-free and available for new and existing cell lines either in service projects or as a license.
The Pathway Modulator Technology is highly versatile and quick. It is readily applicable to any animal cell line and, notably, even to existing producer cell lines, optimizing their productivity. The Pathway Modulator Technology works through the additional expression of an engineered enzyme in the producer cells. Upon stable transfection, the modulator enzymes' concerted action on several cellular pathways results in substantially enhanced volumetric productivities of protein drugs. For various monoclonal antibodies and fusion proteins tested in CHO, the stable modification enhanced yields between 1.5 and 2.6-fold.
The Pathway Modulator Technology can be installed into any existing cell lines, avoiding an entire new cell line development. It lowers upstream manufacturing costs and speeds up drug development through a more rapid supply of larger quantities of bulk drug substance.